Placental STAT3 signaling is activated in women with polycystic ovary syndrome

Human Reproduction

Volumn 30, Issue 3, 2015, Pages 692-700

  Maliqueo, M ^a,b   Sundstrom Poromaa I ^c   Vanky, E ^d,e   Fornes, R ^a   Benrick, A ^a   Akerud H ^c   Stridsklev, S ^d,e   Labrie, F ^f   Jansson, T ^g   Stener Victorin, E ^a,h  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CHILE   (Chile)

^c UPPSALA UNIVERSITY   (Sweden)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f Endoceutics   (Canada)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hyperandrogenemia; Mechanistic target of rapamycin; Polycystic ovary syndrome; Pregnancy; Signal transducer and activator of transcription 3

Indexed keywords

17 BETA DIOL 17 GLUCORONIDE; 17BETA DIOL TESTOSTERONE; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ANDROST 5 ENE 3BETA; ANDROSTANOLONE; ANDROSTENEDIONE; ANDROSTERONE GLUCURONIDE; AROMATASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOKINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTRONE; ESTRONE SULFATE; ETIOCHOLANOLONE GLUCURONIDE; HYDROXY DELTA 5 STEROID DEHYDROGENASE; INITIATION FACTOR 4E BINDING PROTEIN 1; LEPTIN; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PRASTERONE; PRASTERONE SULFATE; PROTEIN S6; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; STAT3 PROTEIN; STEROID DELTA ISOMERASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TESTOSTERONE; UNCLASSIFIED DRUG; MESSENGER RNA; MTOR PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FETUS GROWTH; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MATERNAL BLOOD; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PLACENTA; PLACENTA DISORDER; PREGNANCY OUTCOME; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL; WESTERN BLOTTING; CASE CONTROL STUDY; GENE EXPRESSION; METABOLISM; PHOSPHORYLATION; PREGNANCY;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; PHOSPHORYLATION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84935135385     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu351     Document Type: Article

References (55)

1. Abbott DH, Zhou R, Bird IM, Dumesic DA, Conley AJ. Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome. Endocr Dev 2008;13:145-158.
2. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009;1171:59-76.
3. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004;64:5245-5250.
4. Aye IL, Lager S, Ramirez VI, Gaccioli F, Dudley DJ, Jansson T, Powell TL. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod 2014;90:129.
5. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004a;89:453-462.
6. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004b;89:2745-2749.
7. Babischkin JS, Grimes RW, Pepe GJ, Albrecht ED. Estrogen stimulation of P450 cholesterol side-chain cleavage activity in cultures of human placental syncytiotrophoblasts. Biol Reprod 1997;56:272-278.
8. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001;86:2505-2512.
9. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications inwomen with polycystic ovary syndrome. Semin Reprod Med 2008;26:72-84.
10. Challier JC, Basu S, Bintein T, Minium J, Hotmire K, Catalano PM, Hauguel-de Mouzon S. Obesity inpregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta 2008;29:274-281.
11. Falbo A, Rocca M, Russo T, D'Ettore A, Tolino A, Zullo F, Orio F, Palomba S. Changesinandrogens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes. J Ovarian Res 2010;3:23.
12. Gambino YP, Perez Perez A, Duenas JL, Calvo JC, Sanchez-Margalet V, Varone CL. Regulation of leptin expression by 17beta-estradiol in human placental cells involves membrane associated estrogen receptor alpha. Biochim Biophys Acta 2012;1823:900-910.
13. Gibb W, Lavoie JC. Substrate specificity of the placental microsomal aromatase. Steroids 1980;36:507-519.
14. Hellgren C, Akerud H, Skalkidou A, Sundstrom-Poromaa I. Cortisol awakening response in late pregnancy in women with previous or ongoing depression. Psychoneuroendocrinology 2013;38:3150-3154.
15. Jansson T, Aye IL, Goberdhan DC. The emerging role of mTORC1 signaling in placental nutrient-sensing. Placenta 2012;33(Suppl 2):e23-e29.
16. Jansson N, Rosario FJ, Gaccioli F, Lager S, Jones HN, Roos S, Jansson T, Powell TL. Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies. J Clin Endocrinol Metab 2013;98:105-113.
17. Jones HN, Jansson T, Powell TL. IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2. Am J Physiol Cell Physiol 2009;297:C1228-C1235.
18. Kaptein A, Paillard V, Saunders M. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 1996; 271:5961-5964.
19. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011; 204:558 e551-556.
20. Li MG, Ding GL, Chen XJ, Lu XP, Dong LJ, Dong MY, Yang XF, Lu XE, Huang HF. Association of serum and follicular fluid leptin concentrations with granulosa cell phosphorylated signal transducer and activator of transcription 3 expression in fertile patients with polycystic ovarian syndrome. J Clin Endocrinol Metab 2007;92:4771-4776.
21. 2DDCT method. Methods 2001; 25:402-408.
22. Makieva S, Saunders PT, Norman JE. Androgens in pregnancy: roles in parturition. Hum Reprod Update 2014;20:542-559.
23. Maliqueo M, Echiburú B, Crisosto N, Amigo P, Aranda P, Sánchez F, Sir-Petermann T. Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. Fertil Steril 2009;92:277-282.
24. Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N, Sir-Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013;166:151-155.
25. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25:544-551.
26. Maymo JL, Perez AP, Gambino Y, Calvo JC, Sanchez-Margalet V, Varone CL. Review: leptin gene expression in the placenta-regulation of a key hormone in trophoblast proliferation and survival. Placenta 2011; 32(Suppl 2):S146-S153.
27. Mindnich R, Moller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004;218:7-20.
28. Mrizak I, Grissa O, Henault B, Fekih M, Bouslema A, Boumaiza I, Zaouali M, Tabka Z, Khan NA. Placental infiltration of inflammatory markers in gestational diabetic women. Gen Physiol Biophys 2014;33:169-176.
29. Oden A, Wedel H. Arguments for Fishers permutation test. Ann Stat 1975; 3:518-520.
30. Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. Semin Reprod Med 2011;29:173-186.
31. Padmanabhan V, Veiga-Lopez A. Sheep modelsofpolycystic ovary syndrome phenotype. Mol Cell Endocrinol 2013;373:8-20.
32. Palomba S, Russo T, Falbo A, Di Cello A, Tolino A, Tucci L, La Sala GB, Zullo F. Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome. Hum Reprod 2013;28:2838-2847.
33. Palomba S, Falbo A, Chiossi G, Muscogiuri G, Fornaciari E, Orio F, Tolino A, Colao A, La Sala GB, Zullo F. Lipid profile in nonobese pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. Steroids 2014a;88:36-43.
34. Palomba S, Falbo A, Chiossi G, Tolino A, Tucci L, La Sala GB, Zullo F. Early trophoblast invasion and placentation in women with different PCOS phenotypes. Reprod Biomed Online 2014b;29:370-381.
35. Palomba S, Falbo A, Chiossi G, Orio F, Tolino A, Colao A, La Sala GB, Zullo F. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. J Clin Endocrinol Metab 2014c;99:2942-2951.
36. Pérez-Pérez A, Maymó JL, Gambino YP, Guadix P, Dueñas JL, Varone CL, Sánchez-Margalet V. Activated translation signaling in placenta from pregnant women with gestational diabetes mellitus: possible role of leptin. Horm Metab Res 2013;45:436-442.
37. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013;11:56.
38. Roberts JM, Pearson G, Cutler J, Lindheimer M, Pregnancy NWGo Ro HD. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 2003;41:437-445.
39. Roos S, Jansson N, Palmberg I, Saljo K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J Physiol 2007;582:449-459.
40. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
41. Sathishkumar K, Elkins R, Chinnathambi V, Gao H, Hankins GD, Yallampalli C. Prenatal testosterone-induced fetal growth restriction is associated with down-regulation of rat placental amino acid transport. Reprod Biol Endocrinol 2011;9:110.
42. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002;17:2573-2579.
43. Sir-Petermann T, Echiburu B, Maliqueo MM, Crisosto N, Sanchez F, Hitschfeld C, Carcamo M, Amigo P, Perez-Bravo F. Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome. Hum Reprod 2007;22:1830-1836.
44. Sten T, Kurkela M, Kuuranne T, Leinonen A, Finel M. UDP-glucuronosyltransferases in conjugation of 5alpha-and 5beta-androstane steroids. Drug Metab Dispos 2009;37:2221-2227.
45. Sun M, Maliqueo M, Benrick A, Johansson J, Shao R, Hou L, Jansson T, Wu X, Stener-Victorin E. Maternal androgen excess reduces placental and fetal weights, increases placental steroidogenesis, and leads to long-term health effects in their female offspring. Am J Physiol Endocrinol Metab 2012;303:E1373-E1385.
46. The Expert Committee On The Diagnosis And Classification Of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998;21:S5-S19.
47. Thompson EA, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 1974;249:5373-5378.
48. Tuckey RC. Progesterone synthesis by the human placenta. Placenta 2005; 26:273-281.
49. Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogoy K, Kleggetveit O, Hjelle S, von Brandis P, Eikeland T, Flo K et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010; 95:E448-E455.
50. von Versen-Hoynck F, Rajakumar A, Parrott MS, Powers RW. Leptin affects systemA amino acid transport activity in the human placenta: evidence for STAT3 dependent mechanisms. Placenta 2009;30:361-367.
51. Weber M, Kuhn C, Schulz S, Schiessl B, Schleussner E, Jeschke U, Markert UR, Fitzgerald JS. Expression of signal transducer and activator of transcription 3 (STAT3) and its activated forms is negatively altered in trophoblast and decidual stroma cells derived from preeclampsia placentae. Histopathology 2012;60:657-662.
52. Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang SH, Xiao WF. Endocrine traitsof polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Endocr J 2010;57:201-209.
53. Xing AY, Challier JC, Lepercq J, Cauzac M, Charron MJ, Girard J, Hauguel-de Mouzon S. Unexpected expression of glucose transporter 4 in villous stromal cells of human placenta. J Clin Endocrinol Metab 1998; 83:4097-4101.
54. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067-3073.
55. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007;7:454-465.